[1]马晓刚,孙书焰.清热降浊方联合阿托伐他汀治疗T2DM合并MS的疗效及对CK-MB、SHBG的影响[J].西部中医药,2021,34(07):102-105.[doi:10.12174/j.issn.2096-9600.2021.07.26]
 MA Xiaogang,SUN Shuyan.Clinical Effects of Heat-clearing Turbidity-lowering Prescription Combined with Atorvastatin in Treating T2DM Complicated with MS and Its Influence on CK-MB and SHBG[J].Western Journal of Traditional Chinese Medicine,2021,34(07):102-105.[doi:10.12174/j.issn.2096-9600.2021.07.26]
点击复制

清热降浊方联合阿托伐他汀治疗T2DM合并MS的疗效及对CK-MB、SHBG的影响
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
34
期数:
2021年07期
页码:
102-105
栏目:
衷中参西
出版日期:
2021-07-15

文章信息/Info

Title:
Clinical Effects of Heat-clearing Turbidity-lowering Prescription Combined with Atorvastatin in Treating T2DM Complicated with MS and Its Influence on CK-MB and SHBG
作者:
马晓刚, 孙书焰
上海中医药大学附属龙华医院中医内科,上海 200032
Author(s):
MA Xiaogang, SUN Shuyan
Department of Internal Medicine, Longhua Hospital Shanghai University of TCM, Shanghai 200032, China
关键词:
2型糖尿病代谢综合征清热降浊方阿托伐他汀临床疗效
Keywords:
T2DMMSheat-clearing turbidity-lowering prescriptionatorvastatinclinical effects
分类号:
R587
DOI:
10.12174/j.issn.2096-9600.2021.07.26
摘要:
目的探讨清热降浊方联合阿托伐他汀治疗2型糖尿病(type 2 diabetes mellitus,T2DM)合并代谢综合征(metabolic syndrome,MS)的疗效及对肌酸激酶同工酶(creatine kinase-MB,CK-MB)、血清性激素结合球蛋白(sex hormone-binding globulin,SHBG)的影响。 方法将T2DM合并MS患者100例采用随机数字表法分为观察组和对照组各50例。对照组予阿托伐他汀治疗,观察组在此基础上联用清热降浊方。观察两组患者干预前及干预15周后体质量和体质量指数(body mass index,BMI)、血糖血脂、胰岛β细胞功能、血管内皮细胞功能、CK-MB、SHBG水平。 结果干预后两组患者体质量和BMI较干预前降低,观察组低于对照组(P<0.05);干预后两组患者甘油三酯(triglyceride,TG)、总胆固醇(total cholesterol,TC)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol,HDL-C)、空腹血糖(fasting blood glucose,FBG)、餐后2 h血糖(2-hour postprandial blood glucose,2 h PG)均较干预前改善,且观察组TG、TC、FPG、2 h PG低于对照组,HDL-C高于对照组,差异具有统计学意义(P<0.05);干预后两组患者胰岛素分泌指数(insulin secretion index,HOMA-β)、胰岛素抵抗指数(insulin resistance index,HOMA-IR)、内皮素1(endothelin-1,ET-1)、一氧化氮(nitric oxide,NO)较干预均改善,且观察组改善优于对照组(P<0.05);干预后两组患者CK-MB、SHBG水平较干预前改善,且观察组改善优于对照组(P<0.05)。 结论清热降浊方联合阿托伐他汀对T2DM合并MS患者病情有改善作用,有助于减轻患者体质量,改善BMI、血糖、血脂及胰岛β细胞功能、血管内皮细胞功能,降低CK-MB水平,提高SHBG水平。
Abstract:
ObjectiveTo explore clinical effects of heat-clearing turbidity-lowering prescription and atorvastatin in treating T2DM complicated with MS and its impacts on CK-MB and SHBG. MethodsAll 100 patients with T2DM complicated with MS were divided into the observation group and the control group using random number table method, 50 cases in each group. The control group were treated by atorvastatin, the observation group took heat-clearing turbidity-lowering prescription. To observe body mass, BMI, blood glucose, blood lipid, islets β cell function, function of vascular endothelial cells, the levels of CK-MB and SHBG between both groups before the intervention and 15 weeks after the intervention. ResultsAfter the intervention, body mass and BMI of both groups lowered than these before the intervention, the observation group was lower than the control group (P<0.05); after the intervention, the levels of TG, TC, HDL-C, FBG and 2 h PG of both groups were improved than before the intervention, the observation group was lower than the control group in the levels of TG, TC, FPG and 2hPG, higher than the control group in HDL-C, and the difference has statistical meaning (P<0.05); after the intervention, HOMA-β, HOMA-IR, ET-1 and NO of both groups were improved after the intervention than these before the intervention, and the improvements of the observation group were superior to these of the control group (P<0.05); after the intervention, the levels of CK-MB and SHBG in both groups were improved than these after the intervention, and the improvements of the observation group were better than these of the control group (P<0.05). ConclusionHeat-clearing turbidity-lowering prescription and atorvastatin could improve the conditions of the patients suffering T2DM complicated with MS, it could help reduce body mass of the patients, improve BMI, blood glucose, blood lipid, islets βcell function, the function of vascular endothelial cells, reduce the levels of CK-MB and raise the levels of SHBG.

相似文献/References:

[1]蒋永平.川丹消斑汤联合西药治疗代谢综合征颈动脉粥样硬化疗效观察[J].西部中医药,2013,26(05):100.
 JIANG Yongping.Clinical Observation on ChuanDan XiaoBanTang and Western Medicine in Treating Carotid Atherosclerosis Complicated with Metabolic Syndrome[J].Western Journal of Traditional Chinese Medicine,2013,26(07):100.
[2]祁瑞芳.同型半胱氨酸、超敏 C- 反应蛋白在 2 型糖尿病合并脑梗死预测中的作用[J].西部中医药,2014,27(08):152.
[3]邱勇玉,李应东,赵信科,等.高血压病中医证型与 2 型糖尿病及其相关危险因素分析[J].西部中医药,2014,27(09):75.
[4]李东峰,指导:王志刚.王志刚主任医师治疗2型糖尿病“三级”防治思想辨治心得[J].西部中医药,2015,28(01):29.
[5]周雨聪,指导:刘召.红灵五黄汤治疗2型糖尿病90例[J].西部中医药,2015,28(04):99.
[6]杨国军.黄芪注射液对2型糖尿病患者血管功能及微循环状态的影响[J].西部中医药,2015,28(05):109.
[7]康学东,张瀚文.病证结合探讨2型糖尿病胰岛素抵抗[J].西部中医药,2015,28(11):112.
[8]张喜芬,赵保礼,杨立波,等.通络明目胶囊治疗糖尿病视网膜病变的随机双盲对照研究[J].西部中医药,2013,26(11):88.
 ZHANG Xifen,ZHAO Baoli,YANG Libo,et al.A Randomized, Double-blind and Placebo-controlled Study of TongLuo MingMu Capsule in Treating Diabetic Retinopathy[J].Western Journal of Traditional Chinese Medicine,2013,26(07):88.
[9]张军和,杨振亚,张永琴.安糖1号治疗初发2型糖尿病并代谢综合征40例临床观察[J].西部中医药,2013,26(05):1.
 ZHANGJunhe,YANGZhenya,ZHANGYongqin.ClinicalObservationonAnTangNo.1intheTreatmentfor40CasesofDiabetesMellitusTypeTwoatPrimaryStageComplicatedwithMetabolismSyndrome[J].Western Journal of Traditional Chinese Medicine,2013,26(07):1.
[10]戴梅.全面干预护理对2型糖尿病患者血糖和糖化血红蛋白水平的影响[J].西部中医药,2013,26(07):109.
 DAI Mei.Intervention of Comprehensive Nursing on Blood Glucose and Glycosylated Hemoglobin of Patients with Diabetes Mellitus Type Two[J].Western Journal of Traditional Chinese Medicine,2013,26(07):109.

备注/Memo

备注/Memo:
马晓刚(1980—),男,主治医师。研究方向:内分泌代谢疾病的诊治。
更新日期/Last Update: 2021-07-15